Ποια είναι η τιμή για Zhejiang Taimei Medical Technology Co., Ltd. (2576)

Η τιμή για Zhejiang Taimei Medical Technology Co., Ltd. (2576) είναι $0.67033345

Ποια είναι η κεφαλαιοποίηση αγοράς για Zhejiang Taimei Medical Technology Co., Ltd. (2576)

Η κεφαλαιοποίηση αγοράς για Zhejiang Taimei Medical Technology Co., Ltd. (2576) είναι $377.97M

Zhejiang Taimei Medical Technology Co., Ltd. (2576) Τιμή και Κεφαλαιοποίηση Αγοράς

Zhejiang Taimei Medical Technology Co., Ltd., established in 2013 and based in Jiaxing, China, specializes in delivering sophisticated digital operational platforms specifically designed for the biopharmaceutical industry across the country. The company's core offering is TrialOS, a comprehensive digital collaboration platform that seamlessly integrates all participants throughout the drug development and research lifecycle. This ecosystem effectively links hospitals, pharmaceutical firms, external service providers, regulatory bodies, and patients, among other key industry stakeholders. Its extensive portfolio of software solutions caters to various critical aspects of clinical research and drug development. For streamlining clinical trial operations, Taimei Medical provides tools like eCooperate, which optimizes management systems and leverages big data for informed decision-making. Other related offerings include eArchives for managing master files, eCollect for electronic data capture, eCollege for training administration, eQuality for electronic audit processes, and eBalance for interactive web-based responses. Innovations such as eVisit Patient Reported Outcomes are designed to enhance patient data input and accuracy, while eTime supports project time management, and eImage facilitates medical image interpretation. Furthermore, the company supplies specialized software tailored for hospitals and Good Clinical Practice (GCP) sites. These include eTrial for managing Phase I wards, eSite and NomenCTMS for comprehensive clinical trial management at study sites, and intelligent platforms like GCP-X and Intelligent Investigator. Solutions such as eScreening assist with subject information management and deduplication, while IIT-EDC and the Investigator-Initiated Clinical Trial Management System support investigator-initiated studies and their associated data management. In the crucial domain of drug safety, the company offers robust pharmacovigilance software solutions. This includes both global and intelligent eSafety systems, alongside the SAE Manager for efficient communication and management of critical safety data during clinical trials. Complementing these, Zhejiang Taimei also develops marketing software and a variety of other digital innovation solutions.

Η τιμή για 2576	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$9,447.12 $377.97M	NVDA	$5.327T	+1,409,216.44%
$8,237.72 $377.97M	AAPL	$4.645T	+1,228,798.45%
$7,218.63 $377.97M	GOOG	$4.070T	+1,076,771.86%
$6,711.98 $377.97M	MSFT	$3.785T	+1,001,189.24%
$4,948.30 $377.97M	AMZN	$2.790T	+738,084.91%

Η τιμή για 2576

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$9,447.12 $377.97M